Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of UNCOVER‐3
Journal of the European Academy of Dermatology and Venereology2016Vol. 31(3), pp. 477–482
Citations Over TimeTop 10% of 2016 papers
P.C.M. van de Kerkhof, Lyn Guenther, A.B. Gottlieb, Michael Sebastian, Jashin J. Wu, Peter Foley, Akimichi Morita, Orin M. Goldblum, L. Zhang, J. Erickson, Susan Ball, Phoebe Rich
Abstract
At Week 12, significant improvements in fingernail psoriasis were achieved with ixekizumab therapy. With IXE Q4W maintenance dosing, additional improvement was demonstrated through 60 weeks, and >50% of patients achieved complete resolution. Registered at clinicaltrials.gov: NCT01646177.
Related Papers
- → Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis(2017)7 cited
- Ixekizumab approved for pediatric plaque psoriasis(2020)
- Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis(2017)
- FDA approves ixekizumab for plaque psoriasis(2016)
- Emerging targeted therapies for plaque psoriasis – impact of ixekizumab(2017)